88 related articles for article (PubMed ID: 19918950)
1. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
[TBL] [Abstract][Full Text] [Related]
2. Methylseleninic acid downregulates hypoxia-inducible factor-1α in invasive prostate cancer.
Sinha I; Null K; Wolter W; Suckow MA; King T; Pinto JT; Sinha R
Int J Cancer; 2012 Mar; 130(6):1430-9. PubMed ID: 21500193
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.
Desai D; Kaushal N; Gandhi UH; Arner RJ; D'Souza C; Chen G; Vunta H; El-Bayoumy K; Amin S; Prabhu KS
Chem Biol Interact; 2010 Dec; 188(3):446-56. PubMed ID: 20883674
[TBL] [Abstract][Full Text] [Related]
5. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
6. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.
Gowda R; Madhunapantula SV; Desai D; Amin S; Robertson GP
Mol Cancer Ther; 2013 Jan; 12(1):3-15. PubMed ID: 23112250
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Dandekar DS; Lopez M; Carey RI; Lokeshwar BL
Int J Cancer; 2005 Jun; 115(3):484-92. PubMed ID: 15688368
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
11. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
[TBL] [Abstract][Full Text] [Related]
12. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
13. PAIII prostate tumors express prostate specific antigen (PSA) in Lobund-Wistar rats.
Suckow MA; Wheeler J; Yan M
Can J Vet Res; 2009 Jan; 73(1):39-41. PubMed ID: 19337394
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
15. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
16. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
Cadieux PA; Mikolajczak SA; Reeves J; Strathdee C; Reid G; Panchal CJ; Clarke MW
Cancer Invest; 2006; 24(3):246-55. PubMed ID: 16809150
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.
Zhang Z; Lai GH; Sirica AE
Hepatology; 2004 Apr; 39(4):1028-37. PubMed ID: 15057907
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Anai S; Tanaka M; Shiverick KT; Kim W; Takada S; Boehlein S; Goodison S; Mizokami A; Rosser CJ
J Urol; 2007 May; 177(5):1913-7. PubMed ID: 17437847
[TBL] [Abstract][Full Text] [Related]
20. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
Narayanan NK; Narayanan BA; Reddy BS
Int J Oncol; 2005 Mar; 26(3):785-92. PubMed ID: 15703837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
